Samil Pharm
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inf… Read more
Samil Pharm (000520) - Total Liabilities
Latest total liabilities as of June 2025: ₩226.31 Billion KRW
Based on the latest financial reports, Samil Pharm (000520) has total liabilities worth ₩226.31 Billion KRW as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Samil Pharm - Total Liabilities Trend (2011–2024)
This chart illustrates how Samil Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Samil Pharm Competitors by Total Liabilities
The table below lists competitors of Samil Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AMTD Digital Inc.
NYSE:HKD
|
USA | $344.17 Million |
|
Donglai Coating Technology (Shanghai) Co. Ltd. A
SHG:688129
|
China | CN¥721.11 Million |
|
Vaibhav Global Limited
NSE:VAIBHAVGBL
|
India | ₹6.95 Billion |
|
PLINTAS
KLSE:5320
|
Malaysia | RM3.02 Billion |
|
Guangdong Hotata Technology Group Co Ltd Class A
SHG:603848
|
China | CN¥550.49 Million |
|
LINE Pay Taiwan Limited
TW:7722
|
Taiwan | NT$9.09 Billion |
|
Mountain Commerce Bancorp Inc
OTCQX:MCBI
|
USA | $1.63 Billion |
|
Ceres Power Holdings plc
PINK:CPWHF
|
USA | $27.85 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Samil Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Samil Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Samil Pharm (2011–2024)
The table below shows the annual total liabilities of Samil Pharm from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩218.95 Billion | -9.84% |
| 2023-12-31 | ₩242.85 Billion | +5.19% |
| 2022-12-31 | ₩230.88 Billion | +43.71% |
| 2021-12-31 | ₩160.66 Billion | +25.41% |
| 2020-12-31 | ₩128.11 Billion | +5.35% |
| 2019-12-31 | ₩121.60 Billion | +32.37% |
| 2018-12-31 | ₩91.87 Billion | +8.96% |
| 2017-12-31 | ₩84.31 Billion | +75.19% |
| 2016-12-31 | ₩48.12 Billion | +7.18% |
| 2015-12-31 | ₩44.90 Billion | -15.08% |
| 2014-12-31 | ₩52.88 Billion | +15.75% |
| 2013-12-31 | ₩45.68 Billion | -5.07% |
| 2012-12-31 | ₩48.12 Billion | -11.86% |
| 2011-12-31 | ₩54.60 Billion | -- |